Cohen E, Harrington K, Le Tourneau C, et al. Pembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial. ESMO 2017 Congress; abstract LBA45_PR.
Fase II-onderzoek naar oncolytisch coxsackievirus A21 bij niet-resectabel melanoom
nov 2021 | Dermato-oncologie